Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Toshifumi Ozaki; Axel Hillmann; Christiane Hoffmann; Christian Rübe; Barbara Dockhorn-Dworniczak; Sebastian Blasius; Jürgen Dunst; Jörn Treuner; Herbert Jürgens; Winfried Winkelmann

doi:10.3109/17453679709003970

Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Toshifumi Ozaki^*, Axel Hillmann, Christiane Hoffmann, Christian Rübe, Barbara Dockhorn-Dworniczak, Sebastian Blasius, Jürgen Dunst, Jörn Treuner, Herbert Jürgens, Winfried Winkelmann

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Strahlentherapie

Westfälische Wilhelms-Universität Münster

15 Zitate (Scopus)

Abstract

We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

Originalsprache	Englisch
Zeitschrift	Acta Orthopaedica Scandinavica
Jahrgang	68
Ausgabenummer	1
Seiten (von - bis)	20-24
Seitenumfang	5
ISSN	0001-6470
DOIs	https://doi.org/10.3109/17453679709003970
Publikationsstatus	Veröffentlicht - 1997

Fördermittel

The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant # M43/92/Jii2) and EC BIOMED 1’ (grant # BMHl -CT92-1341).

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.3109/17453679709003970

Weitere Links

Link to publication in Scopus

Zitieren

@article{c6614a9a5ec140528e0e26470f016751,

title = "Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group",

abstract = "We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36\%, 65\%, and 65\% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.",

author = "Toshifumi Ozaki and Axel Hillmann and Christiane Hoffmann and Christian R{\"u}be and Barbara Dockhorn-Dworniczak and Sebastian Blasius and J{\"u}rgen Dunst and J{\"o}rn Treuner and Herbert J{\"u}rgens and Winfried Winkelmann",

note = "Funding Information: The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant \# M43/92/Jii2) and EC BIOMED 1{\textquoteright} (grant \# BMHl -CT92-1341). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "1997",

doi = "10.3109/17453679709003970",

language = "English",

volume = "68",

pages = "20--24",

journal = "Acta Orthopaedica Scandinavica",

issn = "0001-6470",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

AU - Ozaki, Toshifumi

AU - Hillmann, Axel

AU - Hoffmann, Christiane

AU - Rübe, Christian

AU - Dockhorn-Dworniczak, Barbara

AU - Blasius, Sebastian

AU - Dunst, Jürgen

AU - Treuner, Jörn

AU - Jürgens, Herbert

AU - Winkelmann, Winfried

N1 - Funding Information: The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant # M43/92/Jii2) and EC BIOMED 1’ (grant # BMHl -CT92-1341). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 1997

Y1 - 1997

N2 - We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

AB - We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

UR - https://www.scopus.com/pages/publications/8044247185

U2 - 10.3109/17453679709003970

DO - 10.3109/17453679709003970

M3 - Journal articles

C2 - 9057563

AN - SCOPUS:8044247185

SN - 0001-6470

VL - 68

SP - 20

EP - 24

JO - Acta Orthopaedica Scandinavica

JF - Acta Orthopaedica Scandinavica

IS - 1

ER -

Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Abstract

Fördermittel

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren